Cecil Jones's Insider Trades & SAST Disclosures
Cecil Jones's most recent trade in Agios Pharmaceuticals Inc was a trade of 43,500 Stock options (right to buy) done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Cecil Jones.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 15,910 | 15,910 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,510 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 22,437 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 2,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,829 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 594 | 21,843 (0%) | 0% | 35.5 | 21,111 | Common stock |
| Origin Bancorp Inc | Cecil Jones | Director | Grant, award, or other acquisition of securities at price $ 33.85 per share. | 20 Nov 2024 | 733 | 2,733 (0%) | 0% | 33.8 | 24,812 | Common Stock |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2024 | 7,473 | 22,700 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2024 | 7,473 | 7,472 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.03 per share. | 26 Sep 2024 | 2,542 | 20,158 (0%) | 0% | 49.0 | 124,634 | Common stock |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,000 | 4,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,000 | 15,512 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 672 | 14,840 (0%) | 0% | 32.6 | 21,887 | Common stock |
| Agios Pharmaceuticals Inc | Jones Cecilia | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,380 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,380 | 14,955 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jones Cecilia | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,886 | 13,069 (0%) | 0% | 21.6 | 40,813 | Common stock |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,380 | 5,380 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,380 | 5,380 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,597 | 3,783 (0%) | 0% | 28.4 | 45,291 | Common stock |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,000 | 22,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 6,000 | 6,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2022 | 118,390 | 118,390 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2022 | 22,417 | 22,417 | - | - | Restricted stock units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges